PPAR-γ plays a critical role in glucose homeostasis and is a molecular target of insulin sensitizing drugs called thiazolidinediones which are PPAR-γ ligands. PPAR-γ ligands also upregulate expression of adipocyte glycerol kinase, resulting into improved insulin action in target tissue such as liver and muscle. PPAR-γ ligand also shown to augment glucose disposal in peripheral tissues by increasing expressions of the glucose transporter genes, GLUT-1 and GLUT-4. Majority of the Diabetes Mellitus Type 2 (DM type 2) patients (80%) are obese, but all obese persons do not develop DM type 2. Serum adiponectin level should be determined by level of PPAR-γ activity in adipocytes. Therefore it will be of interest to explore the difference in the level of serum PPAR-γ level between obese subjects with DM-2 and without DM-2, as both the insulin sensitizing factor’s adiponectin, and vistafin are synthesized in response to FFA. PPAR-γ complex receptor activity. Estimation of serum PPAR- γ level alongwith FBG was done in 90 cases, of which 30 were normal healthy subjects, 30 obese without diabetes type 2 and 30 obese with diabetes type 2. The qualitative estimation of PPAR-γ in human serum was done by ELISA method using ELISA kit from E lab science Biotechnology Co.Ltd. In our study we found a significant change in the level of PPAR- γ between the obese with DM-2 and control subject and also between obese without DM-2 and control subject but we did not find any significant difference between obese with DM-2 and obese without DM-2. In our present study we found the Increased Levels of PPAR- γ in the Obese without Diabetes Mellitus and Obese with Diabetes Mellitus. The levels were 8.03ng/ml ±11.16 and 8.04ng/ml±10.94 respectively. Finally, we observed that the level of PPAR- γ is increased with both the groups, i.e. obese without DM-2 and obese with DM-2 in comparison to normal subjects.